Mutated Retroviral Envelope Display for Targeted Gene Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing methods for screening cells, particularly T cells, for specific antigens and delivering nucleic acids to target cells are inefficient and lack target-specificity, requiring recombinant expression of T cell receptors and limited throughput.
Innovation Solution
Retroviruses are engineered with mutated envelope proteins and non-viral membrane-bound proteins with extracellular targeting domains to enable specific binding and entry into target cells, allowing for high-throughput screening and targeted nucleic acid delivery without recombinant TCR expression.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If retroviruses are pseudotyped with wild-type envelope proteins (e.g., VSV-G), then broad cellular tropism and high transduction efficiency are achieved, but target-specific binding and reduced off-target effects are lost
Solution Approach 1:
The patent applies parameter changes by introducing specific mutations in the envelope protein sequence to alter binding affinity and specificity. Mutations such as K47Q, R354A, and R354Q in VSV-G are implemented to reduce off-target binding while maintaining or enhancing target cell specificity, directly addressing the contradiction between broad tropism and targeted delivery
Solution Approach 2:
The patent applies local quality by creating heterogeneous virus populations with different envelope protein variants. Each virus particle may have slightly different binding properties, allowing the system to achieve both broad coverage and specific target engagement through the diversity of local binding characteristics across the viral population
2Measurement precision
If conventional screening methods are used for T cell antigen specificity, then detailed T cell receptor characterization is achieved, but throughput is limited and recombinant TCR expression is required
Solution Approach 1:
The patent applies the intermediary principle by using engineered retroviruses as mediators between the screening system and T cells. These viruses carry envelope proteins that specifically bind to T cell receptors, serving as intermediaries that enable high-throughput screening without requiring complex recombinant TCR expression systems. The viral envelope acts as a bridge that simplifies the screening workflow while maintaining measurement precision
Solution Approach 2:
The patent applies copying by creating viral copies of envelope proteins that mimic natural ligand-receptor interactions. Instead of requiring full recombinant TCR expression, the system uses simplified envelope protein copies on viral surfaces that replicate the essential binding properties, enabling high-throughput screening through easier viral production and delivery
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Enables high-throughput screening of T cells for antigen specificity and targeted nucleic acid delivery to cells, overcoming previous limitations by allowing screening of >10^8 ligands without recombinant TCR expression, and reducing off-target effects.
Implementation Method 1
a mutated viral envelope protein comprising at least one mutation that diminishes its native function
Data Source
AI summary
Compositions of retroviruses and methods of using the same for gene delivery, wherein the retroviruses comprise a viral envelope protein comprising at least one mutation that diminishes its native function, a non-viral membrane-bound protein comprising a membrane-bound domain and an extracellular targeting domain.